Given the prominent roles of MDSCs in chronic inflammation and immunosuppression as well as their critical importance in cancer immunotherapies (2–8), the above evidence led us to test the hypothesis that TRAF3 expressed in myeloid cells can negatively regulate MDSC expansion during chronic inflammation. Here, TRAF3 is linked to cancer.